GlassScriptPhysician profile
Saveen Sall
NPI 1326617663
$1,427.22
in general payments reported to CMS, 2019-2025
15 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $321 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,427.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $346.83 | 2024-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $301.17 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $220.06 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $115.47 | 2025 | Austedo Xr |
| Lundbeck LLC | $105.97 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $86.42 | 2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $51.57 | 2024-2025 | Onyda Xr, Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $51.45 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $36.30 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $29.92 | 2025 | Cobenfy |
| Corium, LLC | $18.37 | 2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $17.92 | 2025 | Invega Sustenna |
| Abbvie INC. | $16.10 | 2025 | |
| Indivior INC. | $14.84 | 2024 | Perseris |
| Livanova USA, INC. | $14.83 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saveen Sall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.